Determination of the Absolute Bioavailability of GSK1120212 Following a Single Oral Dose Co-Administered With an Intravenous Radiolabelled Microdose of GSK1120212 in Subjects With Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 15 Nov 2017
At a glance
- Drugs Trametinib (Primary) ; Trametinib (Primary)
- Indications Solid tumours
- Focus Pharmacokinetics
- Sponsors GlaxoSmithKline
- 13 Apr 2012 Actual patient number added 4 according to ClinicalTrials.gov.
- 13 Apr 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 13 Apr 2012 Actual end date (December 2011) added as reported by ClinicalTrials.gov.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History